Symbols

SLXN

Silexion·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About SLXN

Silexion Therapeutics Corp

A clinical stage biotechnology company specializing in oncology

Industry

Biological Technology

Established Date

Listing Date

04/07/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.silexion.com

Security Type

Common stock

Office address

12 Abba Hillel Road, Ramat-Gan, Israel 5250606

Business

Introduction

Silexion Therapeutics Corp is a Cayman Islands exempted company. The Company is a clinical-stage, oncology-focused biotechnology company developing proprietary therapies for KRAS mutation-driven cancers. Its lead drug candidate, SIL204, is a second-generation small interfering RNA designed to inhibit production of the mutant KRAS protein, initially targeting locally advanced pancreatic cancer.

Company Financials

EPS

SLXN has released its 2025 Q4 earnings. EPS was reported at -1.4, versus the expected -0.25, missing expectations. The chart below visualizes how SLXN has performed over recent quarters, highlighting trends in earnings surprises.